Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

Not Applicable

Not yet recruiting

• Conditions: Non-segmental Vitiligo
• Interventions: Drug: VC005 tablets; Drug: VC005 Tablets Placebo

• Registration Number: NCT07172347
• Lead Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Brief Summary

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-08
• Study First Submitted QC: 2025-09-08
• Last Update Submitted: 2025-09-08
• Study First Posted: 2025-09-15
• Last Update Posted: 2025-09-15
• Study Start: 2025-10-20
• Primary Completion: 2027-08-30
• Study Completion: 2027-08-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.
• The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.

Exclusion Criteria

• Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
• All hair in the vitiligo area on the face is white.
• Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.
• Subjects who have previously received depigmentation treatment.
• Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VC005 Tablets Low Dose groups	VC005 tablets	-
VC005 Tablets Placebo groups	VC005 Tablets Placebo	-
VC005 Tablets High Dose groups	VC005 tablets	-

Primary Outcome Measures

Name	Time	Method
Percentage change in facial vitiligo area score index (F-VASI) relative to baseline at week 24	Week 24

Trial Locations

Locations (1)

The Peking University People's Hospital; 🇨🇳 Beijing, Beijng, China